Physician profile
Diane Ackroyd
NPI 1083655815
$1,734.31
in general payments reported to CMS, 2019-2025
14 companies · $779 in 2025
The $779 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $488 · 2023: $149 · 2024: $319 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,246.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $514.29 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $324.38 | 2023-2025 | Spravato |
| Alkermes, INC. | $205.36 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $163.82 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $128.23 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $104.81 | 2025 | Hetlioz, Fanapt |
| Supernus Pharmaceuticals, INC. | $89.44 | 2025 | |
| Lundbeck LLC | $47.34 | 2024-2025 | Rexulti |
| Corium, LLC | $46.20 | 2024 | Azstarys |
| Janssen Scientific Affairs, LLC | $34.08 | 2025 | Spravato |
| Owp Pharmaceuticals, INC. | $23.62 | 2023 | Lamotrigine, Subvenite |
| Bausch Health US, LLC | $22.98 | 2025 | Aplenzin |
| Axsome Therapeutics, INC. | $14.90 | 2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $14.86 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Ackroyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.